BerGenBio has announced that the first COVID-19 patient was dosed with bemcentinib in a phase 2 trial to evaluate the drug as a potential treatment.
The study will assess the oral kinase inhibitor in addition to standard of care. It will recruit 120 hospitalized COVID-19 patients, giving 60 participants bemcentinib in addition to the standard of care, while the others will receive only the standard of care.
Bemcentinib is the first candidate to be tested as a part of the UK’s Accelerating COVID-19 Research & Development (ACCORD) platform trial of multiple early-stage COVID-19 treatments.
The company expects to release topline results later this summer.
Two AstraZeneca drugs have also been chosen for evaluation under the ACCORD program: AZ’s cancer treatment Calquence (acalabrutinib) and an investigational diabetic kidney disease treatment MEDI3506 (DID, May 4). — Jordan Williams